S. P. Ardoin, J. C. Shanahan, and D. S. Pisetsky, The Role of Microparticles in Inflammation and Thrombosis, Scand J Immunol. août, vol.66, issue.2-3, pp.159-65, 2007.

J. Atkinson, G. Siest, C. Vigneron, R. Bonaly, P. Dixneuf et al., Evaluation et caractérisation de trois méthodes d'étude des microparticules procoagulantes chez des patients en phase aiguë de l'AVC ischémique, p.105

, Apport de la numération des microparticules plaquettaires par cytométrie en flux pour le diagnostic des syndromes myéloprolifératifs Ph1

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood. 19 mai, vol.127, issue.20, pp.2391-405, 2016.

V. Ugo, C. James, and W. Vainchenker, Une mutation unique de la protéine kinase JAK2 dans la polyglobulie de Vaquez et les syndromes myéloprolifératifs non-LMC. médecine/sciences, juin, vol.21, issue.6-7, pp.669-70, 2005.

C. James, U. V. , L. Couédic, J. Staerk, J. Delhommeau et al., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature. avr, vol.434, issue.7037, pp.1144-1152, 2005.

Y. Pikman, B. H. Lee, T. Mercher, E. Mcdowell, B. L. Ebert et al., MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. Sawyers C, éditeur, PLoS Med. 18 juill, vol.3, issue.7, p.270, 2006.

T. Klampfl, H. Gisslinger, A. S. Harutyunyan, H. Nivarthi, E. Rumi et al., Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, N Engl J Med. 19 déc, vol.369, issue.25, pp.2379-90, 2013.

A. Casini, P. Fontana, and T. P. Lecompte, Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management, J Thromb Haemost. juill, vol.11, issue.7, pp.1215-1242, 2013.

A. M. Vannucchi and P. Guglielmelli, JAK2 Mutation-Related Disease and Thrombosis, Semin Thromb Hemost. juill, vol.39, issue.5, pp.496-506, 2013.

R. Marchioli, G. Finazzi, R. Landolfi, J. Kutti, H. Gisslinger et al., Vascular and neoplastic risk in a large cohort of patients with polycythemia vera, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.23, issue.10, pp.2224-2256, 2005.

V. D. Stefano, T. Za, E. Rossi, A. M. Vannucchi, M. Ruggeri et al., Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments, Haematologica. 1 mars, vol.93, issue.3, pp.372-80, 2008.

C. Besses, F. Cervantes, A. Pereira, L. Florensa, F. Solé et al., Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients, Leukemia. févr, vol.13, issue.2, pp.150-154, 1999.

S. Cortelazzo, G. Finazzi, M. Ruggeri, O. Vestri, M. Galli et al., Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis, N Engl J Med. 27 avr, vol.332, issue.17, pp.1132-1139, 1995.

J. J. Michiels, U. Budde, M. Van-der-planken, H. H. Van-vliet, W. Schroyens et al., Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management, Best Pract Res Clin Haematol. juin, vol.14, issue.2, pp.401-437, 2001.

S. L. Etheridge, M. E. Roh, M. E. Cosgrove, V. Sangkhae, N. E. Fox et al., JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms, Proc Natl Acad Sci U S A. 11 févr, vol.111, issue.6, pp.2295-300, 2014.

A. Wehmeier, S. Fricke, R. E. Scharf, and W. Schneider, A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders, Eur J Haematol, vol.45, issue.4, pp.191-198, 1990.

A. I. Schafer, Bleeding and thrombosis in the myeloproliferative disorders, Blood. juill, vol.64, issue.1, pp.1-12, 1984.

A. Falanga, M. Marchetti, V. Evangelista, A. Vignoli, M. Licini et al., Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera, Blood. 15 déc, vol.96, issue.13, pp.4261-4267, 2000.

T. Barbui, A. Carobbio, A. Rambaldi, and G. Finazzi, Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?, Blood. 23 juill, vol.114, issue.4, pp.759-63, 2009.

M. K. Jensen, P. Brown, B. V. Lund, O. J. Nielsen, and H. C. Hasselbalch, Increased circulating plateletleukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count, Eur J Haematol. 1 mars, vol.66, issue.3, pp.143-51, 2001.

M. C. Trappenburg, M. Van-schilfgaarde, M. Marchetti, H. M. Spronk, H. Cate et al., Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia, Haematologica. 1 juill, vol.94, issue.7, pp.911-919, 2009.

M. Marchetti, E. Castoldi, H. Spronk, . Oerle-r-van, D. Balducci et al., Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera, Blood, vol.112, issue.10, pp.4061-4069, 2008.

J. Duchemin, V. Ugo, J. Ianotto, L. Lecucq, B. Mercier et al., Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms, Thromb Res. 1 sept, vol.126, issue.3, pp.238-280, 2010.

F. Cervantes, E. Arellano-rodrigo, and A. Alvarez-larrán, Blood cell activation in myeloproliferative neoplasms, Haematologica. nov, vol.94, issue.11, pp.1484-1492, 2009.

B. Robertson, C. Urquhart, I. Ford, J. Townend, H. G. Watson et al., Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies, J Thromb Haemost JTH. août, vol.5, issue.8, pp.1679-85, 2007.

A. Falanga, M. Marchetti, A. Vignoli, D. Balducci, L. Russo et al., V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules, Exp Hematol. mai, vol.35, issue.5, pp.702-713, 2007.

A. Piccin, W. G. Murphy, and O. P. Smith, Circulating microparticles: pathophysiology and clinical implications, Blood Rev. mai, vol.21, issue.3, pp.157-71, 2007.

O. Morel, N. Morel, B. Hugel, L. Jesel, S. Vinzio et al., Les microparticules circulantes : rôles physiologiques et implications dans les maladies inflammatoires et thrombotiques. Rev Médecine Interne, vol.26, pp.791-801, 2005.

J. Simak, M. P. Gelderman, H. Yu, V. Wright, and A. E. Baird, Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome, J Thromb Haemost. juin, vol.4, issue.6, pp.1296-302, 2006.

A. Leroyer, A. Tedgui, and C. Boulanger, Microparticules plasmatiques : marqueurs et effecteurs de l'atteinte vasculaire, vol.2, p.9, 2018.

J. Quilici, N. Banzet, P. P. Meynard, J. Mutin, M. Bonnet et al., Circulating Endothelial Cell Count as a Diagnostic Marker for Non-ST-Elevation Acute Coronary Syndromes, Circulation. 21 sept, vol.110, issue.12, pp.1586-91, 2004.

L. Bernal-mizrachi, W. Jy, J. J. Jimenez, J. Pastor, L. M. Mauro et al., High levels of circulating endothelial microparticles in patients with acute coronary syndromes, Am Heart J. juin, vol.145, issue.6, pp.962-70, 2003.

Z. Mallat, H. Benamer, B. Hugel, J. Benessiano, P. G. Steg et al., Elevated Levels of Shed Membrane Microparticles With Procoagulant Potential in the Peripheral Circulating Blood of Patients With Acute Coronary Syndromes, Circulation. 29 févr, vol.101, issue.8, pp.841-844, 2000.

T. Villmow, B. Kemkes-matthes, and A. C. Matzdorff, Markers of platelet activation and plateletleukocyte interaction in patients with myeloproliferative syndromes, Thromb Res, vol.108, issue.2-3, pp.139-184, 2002.

J. A. Chirinos, G. A. Heresi, H. Velasquez, W. Jy, J. J. Jimenez et al., Elevation of Endothelial Microparticles, Platelets, and Leukocyte Activation in Patients With Venous Thromboembolism, J Am Coll Cardiol. mai, vol.45, issue.9, pp.1467-71, 2005.

L. Daniel, Y. Berda-haddad, V. Faure, P. Brunet, Y. Berland et al., , p.18

A. Dieri, R. De-laat, B. Hemker, and H. C. , Thrombin generation: what have we learned?, Blood Rev. sept, vol.26, issue.5, pp.197-203, 2012.

A. Membré, D. Wahl, T. Lecompte, and V. Regnault, Test de génération de thrombine La thrombinographie, Méthodologie. Rev Francoph Lab. 1 juin, issue.393, pp.37-43, 2007.

G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark, Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement, Thromb Res. mai, vol.127, issue.5, pp.457-65, 2011.

R. G. Hanshaw and B. D. Smith, New reagents for phosphatidylserine recognition and detection of apoptosis, Bioorg Med Chem. sept, vol.13, issue.17, pp.5035-5077, 2005.

Y. Yuana, R. Bertina, and S. Osanto, Pre-analytical and analytical issues in the analysis of blood microparticles, Thromb Haemost, vol.105, issue.03, pp.396-408, 2011.

H. Delacour, A. Servonnet, A. Perrot, J. F. Vigezzi, and J. M. Ramirez, La courbe ROC (receiver operating characteristic) : principes et principales applications en biologie clinique, Ann Biol Clin, vol.63, p.10, 2005.

F. Lussana, S. Caberlon, C. Pagani, P. W. Kamphuisen, H. R. Büller et al., Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review, Thromb Res. sept, vol.124, issue.4, pp.409-426, 2009.

A. Tefferi and M. Elliott, Thrombosis in Myeloproliferative Disorders: Prevalence, Prognostic Factors, and the Role of Leukocytes and JAK2 V617F, Semin Thromb Hemost. juin, vol.33, issue.4, pp.313-333, 2007.

M. Marchetti, C. J. Tartari, L. Russo, M. Panova-noeva, A. Leuzzi et al., Phospholipiddependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia, Am J Hematol. janv, vol.89, issue.1, pp.68-73, 2014.

P. J. Campbell, C. Maclean, P. A. Beer, G. Buck, K. Wheatley et al., Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort, Blood. 16 août, vol.120, issue.7, pp.1409-1420, 2012.

, Serment d'Hippocrate

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer

, Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses; que je sois déshonoré et méprisé si j'y manque